Earnings Releases

Date Headline
5/2/2024
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
 Summary
Reported $420.5 million in cash resources as of March¬†31, 2024 , which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 Completion of rolling biologics license application (BLA) filing with the U.S.  Continue Reading
3/6/2024
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
 Summary
Reported $456.3 million in cash resources as of December 31, 2023 , which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 Initiation of rolling biologics license application (BLA) filing with the FDA for zanidatamab as second-line  Continue Reading